Comment by adamredwoods
3 years ago
Car-T seems promising for leukemia and lymphoma, but not as efficacious in solid tumors:
https://www.lls.org/treatment/types-treatment/immunotherapy/...
Also 2nd gen BTK inhibitors:
3 years ago
Car-T seems promising for leukemia and lymphoma, but not as efficacious in solid tumors:
https://www.lls.org/treatment/types-treatment/immunotherapy/...
Also 2nd gen BTK inhibitors:
BTK inhibitors are technically in 3rd gen (noncovalent) already if you can get in the trials (which are very promising considering they use the same mechanism).